Knight Therapeutics Reports Second Quarter 2026 Results

Increased 2026 guidance and expect revenues of $540 million to $560 millionAchieved six month record-high revenues of $293 million and Adjusted EBITDA1 of $52 million MONTREAL, Aug. 06, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a pan-American (ex-US) pharmaceutical company, today reported financial results for its second quarter ended June […]